Abstract Number: 0061 • ACR Convergence 2024
Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways
Background/Purpose: Transcriptional profiling represents a powerful tool for deciphering disease-relevant pathways and deriving functional biomarkers. Given the shared demographic, genetic, and clinico-epidemiologic features between rheumatoid…Abstract Number: 0344 • ACR Convergence 2024
Characteristics of Patients with Antisynthetase Antibodies
Background/Purpose: Aminoacyl transfer RNA synthetase antibodies (ASAbs) are associated with a range of clinical manifestations, including severe lung and muscle disease and are postulated to…Abstract Number: 0799 • ACR Convergence 2024
Peripheral Biomarker Signatures and a Genetic Risk Score Improve the Identification of RA-ILD Beyond Clinical Risk Factors
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Despite the paucity of known risk…Abstract Number: 0968 • ACR Convergence 2024
Proteomic, Transcriptomic, and Functional Characterization of Circulating Extracellular Vesicles in Progressive Scleroderma Interstitial Lung Disease
Background/Purpose: Progressive pulmonary fibrosis (ILD) is a leading cause of mortality in systemic sclerosis (SSc), particularly in the 30% of ILD patients who exhibit a…Abstract Number: 1424 • ACR Convergence 2024
Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD
Background/Purpose: Genetic studies in various systemic autoimmune rheumatic diseases (SARDs) support that human leukocyte antigen (HLA) class II alleles are associated with specific autoimmune disorders…Abstract Number: 1713 • ACR Convergence 2024
Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Propensity Score-Matched Study Using National Veterans Affairs Data
Background/Purpose: Recent RA-interstitial lung disease (RA-ILD) treatment guidelines noted a paucity of evidence on the comparative effectiveness and safety of DMARDs in RA-ILD. Previously, TNFi…Abstract Number: 2249 • ACR Convergence 2024
Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry
Background/Purpose: The available data on the impact of JAK inhibitors (JAKi) on rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are currently limited. This study aimed to…Abstract Number: 2613 • ACR Convergence 2024
Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Background/Purpose: RA is associated with several forms of parenchymal lung disease, including interstitial lung disease (ILD), bronchiectasis, and emphysema. Acute COVID-19 and other respiratory viruses…Abstract Number: 0062 • ACR Convergence 2024
Pro-Fibrotic Effects of Malondialdehyde-Acetaldehyde-Adducted and/or Citrullinated Proteins on Macrophages and Human Lung Fibroblasts
Background/Purpose: Clinically evident rheumatoid arthritis-associated interstitial lung disease (RA-ILD) affects approximately 10-15% of patients with rheumatoid arthritis (RA) and accounts for the most overrepresented cause…Abstract Number: 0348 • ACR Convergence 2024
Upadacitinib in Interstitial Lung Disease Associated with Idiopathic Inflammatory Myopathies
Background/Purpose: Interstitial lung disease (ILD) is one of the most severe complications in idiopathic inflammatory myopathies (IIM), substantially contributing to the morbidity and mortality. ILD…Abstract Number: 0801 • ACR Convergence 2024
Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Background/Purpose: Neutrophil activation is seen in rheumatoid arthritis (RA), but its involvement in RA interstitial lung disease (RA-ILD) is not clear. Levels of N-formyl methionine…Abstract Number: 0978 • ACR Convergence 2024
Associations of Fire Smoke and Other Pollutants with Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: Wildfires have burned increasing acreage in the United States (US) since the 1980s, releasing record and alarming levels of particulate matter smaller than 2.5…Abstract Number: 1425 • ACR Convergence 2024
Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic
Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the…Abstract Number: 1736 • ACR Convergence 2024
Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstitial Lung Disease Secondary to Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis: A Multi-Center Cohort Study with Propensity Score-Based Inverse Probability of Treatment Weighting
Background/Purpose: The current management of anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+DM) is challenging and largely empirical rather than evidence-based. Small-sized proof-of-concept trial and case series…Abstract Number: 2276 • ACR Convergence 2024
Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists
Background/Purpose: Interstitial lung disease (ILD) is among the most common extra-articular manifestations of RA, with symptomatic disease prevalent in approximately 10% of patients.1 Patients with…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 39
- Next Page »